Published in Women's Health Weekly, December 19th, 2002
The U.K. Medicines Control Agency (MCA) was the Reference Member State for the MR application with Austria, Germany, Italy, Portugal, and Spain as Concerned Member States.
With this news, Arimidex will become the first and only aromatase inhibitor available for use in the adjuvant treatment of early invasive breast cancer in postmenopausal women in these E.U. countries, giving physicians and patients a real choice for treatment. It is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly